Crovalimab: A Novel Approach in the Management of Paroxysmal Nocturnal Hemoglobinuria
ABSTRACT Background and Aims Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare acquired clonal blood disorder caused by mutations in the PIGA gene, leading to complement‐mediated hemolysis. Currently available terminal complement inhibitors, such as Eculizumab and Ravulizumab, pose several challen...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-07-01
|
| Series: | Health Science Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/hsr2.70986 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|